Vanguard Group
PGNX

Vanguard Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Vanguard Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,745,266
Closed -$21.8M – 4117
2020
Q1 		$21.8M Buy
5,745,266
+41,315
+0.7% +$178K ﹤0.01% 2243
2019
Q4 		$29M Buy
5,703,951
+50,590
+0.9% +$268K ﹤0.01% 2354
2019
Q3 		$28.6M Buy
5,653,361
+189,657
+3% +$946K ﹤0.01% 2307
2019
Q2 		$33.7M Buy
5,463,704
+364,803
+7% +$1.76M ﹤0.01% 2293
2019
Q1 		$23.7M Buy
5,098,901
+1,541,314
+43% +$6.97M ﹤0.01% 2423
2018
Q4 		$14.9M Sell
3,557,587
-1,488,844
-30% -$7.58M ﹤0.01% 2581
2018
Q3 		$31.6M Buy
5,046,431
+727,575
+17% +$5.59M ﹤0.01% 2362
2018
Q2 		$34.7M Buy
4,318,856
+278,661
+7% +$2.13M ﹤0.01% 2316
2018
Q1 		$30.1M Sell
4,040,195
-29,405
-0.7% -$196K ﹤0.01% 2336
2017
Q4 		$24.2M Sell
4,069,600
-301,421
-7% -$1.83M ﹤0.01% 2418
2017
Q3 		$32.2M Buy
4,371,021
+70,543
+2% +$448K ﹤0.01% 2272
2017
Q2 		$29.2M Buy
4,300,478
+167,708
+4% +$1.24M ﹤0.01% 2291
2017
Q1 		$39M Buy
4,132,770
+1,304,487
+46% +$13M ﹤0.01% 2124
2016
Q4 		$24.4M Buy
2,828,283
+48,806
+2% +$361K ﹤0.01% 2335
2016
Q3 		$17.6M Buy
2,779,477
+42,086
+2% +$254K ﹤0.01% 2421
2016
Q2 		$11.6M Buy
2,737,391
+241,227
+10% +$1.16M ﹤0.01% 2588
2016
Q1 		$10.9M Buy
2,496,164
+122,039
+5% +$543K ﹤0.01% 2574
2015
Q4 		$14.6M Buy
2,374,125
+34,224
+1% +$224K ﹤0.01% 2442
2015
Q3 		$13.4M Buy
2,339,901
+72,979
+3% +$560K ﹤0.01% 2454
2015
Q2 		$16.9M Buy
2,266,922
+46,154
+2% +$279K ﹤0.01% 2435
2015
Q1 		$13.3M Buy
2,220,768
+126,001
+6% +$793K ﹤0.01% 2505
2014
Q4 		$15.8M Buy
2,094,767
+32,179
+2% +$193K ﹤0.01% 2346
2014
Q3 		$10.7M Buy
2,062,588
+141,126
+7% +$703K ﹤0.01% 2459
2014
Q2 		$8.28M Buy
1,921,462
+65,664
+4% +$251K ﹤0.01% 2591
2014
Q1 		$7.59M Buy
1,855,798
+388,831
+27% +$1.99M ﹤0.01% 2618
2013
Q4 		$7.82M Sell
1,466,967
-38,531
-3% -$170K ﹤0.01% 2564
2013
Q3 		$7.57M Buy
1,505,498
+248,814
+20% +$1.35M ﹤0.01% 2526
2013
Q2 		$5.61M Buy
+1,256,684
New +$5.64M ﹤0.01% 2601

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Vanguard Group's PGNX Position: Q2 2020 in Review

Vanguard Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 5,745,266 shares — an estimated $21.8M sold.

Vanguard Group first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $39M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Vanguard Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Vanguard Group sold 5,745,266 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $21.8M.
  • Vanguard Group first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Vanguard Group's Progenics Pharmaceuticals Inc position peaked at $39M in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Vanguard Group's 13F filing for Q2 2020, filed 14 Aug 2020.